A1 Refereed original research article in a scientific journal
Development of Porous Silicon Nanocarriers for Parenteral Peptide Delivery
Authors: Kovalainen M, Monkare J, Kaasalainen M, Riikonen J, Lehto VP, Salonen J, Herzig KH, Jarvinen K
Publisher: AMER CHEMICAL SOC
Publication year: 2013
Journal: Molecular Pharmaceutics
Journal name in source: MOLECULAR PHARMACEUTICS
Journal acronym: MOL PHARMACEUT
Number in series: 1
Volume: 10
Issue: 1
First page : 353
Last page: 359
Number of pages: 7
ISSN: 1543-8384
DOI: https://doi.org/10.1021/mp300494p(external)
Abstract
Porous silicon (PSi) is receiving growing attention in biomedical research, for example, in drug and peptide delivery. Inspired by several advantages of PSI, herein, thermally oxidized (TOPSi, hydrophilic), undecylenic acid-treated thermally hydro-carbonized (UnTHCPSi, moderately hydrophilic), and thermally hydrocarbonized (THCPSi, hydrophobic) PSI nanocarriers are investigated for sustained subcutaneous (sc) and intravenous (iv) peptide delivery. The route of administration is shown to affect drastically peptide YY3-36 (PYY3-36) release from the PSi nanocarriers in mice. Subcutaneous nanocarriers are demonstrated to be capable to sustain PYY3-36 delivery over 4 days, with the high absolute bioavailability values of PYY3-36. The pharmacokinetic parameters of PYY3-36 are presented to be similar between the sc PSI nanocarriers despite surface chemistry. In contrast, iv-delivered PSi nanocarriers display significant differences between the surface types. Overall, these results demonstrate the feasibility of PSi nanocarriers for the sustained sc delivery of peptides.
Porous silicon (PSi) is receiving growing attention in biomedical research, for example, in drug and peptide delivery. Inspired by several advantages of PSI, herein, thermally oxidized (TOPSi, hydrophilic), undecylenic acid-treated thermally hydro-carbonized (UnTHCPSi, moderately hydrophilic), and thermally hydrocarbonized (THCPSi, hydrophobic) PSI nanocarriers are investigated for sustained subcutaneous (sc) and intravenous (iv) peptide delivery. The route of administration is shown to affect drastically peptide YY3-36 (PYY3-36) release from the PSi nanocarriers in mice. Subcutaneous nanocarriers are demonstrated to be capable to sustain PYY3-36 delivery over 4 days, with the high absolute bioavailability values of PYY3-36. The pharmacokinetic parameters of PYY3-36 are presented to be similar between the sc PSI nanocarriers despite surface chemistry. In contrast, iv-delivered PSi nanocarriers display significant differences between the surface types. Overall, these results demonstrate the feasibility of PSi nanocarriers for the sustained sc delivery of peptides.
UTU Research Portal